Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a relatively new class of medications used for the management of type II diabetes mellitus targeting the kidneys. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.